Medtronic's (MDT) Brain Therapies Device Receives FDA Approval
Zacks Investment Research | Dec 18, 2019 08:58PM ET
Medtronic plc (NYSE:MDT) received the FDA’s approval for its Stealth Autoguide system, which integrates with its enabling technology portfolio to develop an end-to-end procedural solution. With the recent clearance, the company aims to strengthen its brain therapies business by enhancing focus on the robotics platform globally.
Notably, the brain therapies business is part of Medtronic’s broader Restorative Therapies Group segment.
Stealth Autoguide at a Glance
The Stealth Autoguide system, which is a robotic guidance system, is intended to be used for the spatial positioning and orientation of instrument holders or tool guides used in neurosurgical procedures.
Per the company, the Stealth Autoguide system can now be used for biopsy procedures, stereoelectroencephalography (sEEG) depth electrode placement and the positioning of the Visualase bone anchor used for catheter placement. The solutions are part of Medtronic’s surgical synergy platform that integrates the company’s technologies to create consistent, predictable and reproducible procedures.
Significance of the Approval
The Stealth Autoguide system integrates with StealthStation Image Guidance systems and the Midas Rex high-speed surgical drill platform. The navigation software enhances surgical workflow, thus providing continuous real-time navigation and visual feedback on robotic positioning for better efficiency.
Per the medical fraternity, the FDA nod will help clinicians to perform unique surgical procedures with increased accuracy as the system provides visualization throughout the procedure, with the ability to drill on the axis of a surgical plan.
Industry Prospects
Per a report by Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.